Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tapectam is a combination antibiotic product marketed in Colombia, consisting of piperacillin, a broad-spectrum penicillin-class antibiotic, and tazobactam, a beta-lactamase inhibitor. Piperacillin works by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the third and last stage of bacterial cell wall synthesis. Tazobactam is a penicillanic acid sulfone derivative that functions as a suicide inhibitor of many beta-lactamases, which are enzymes produced by bacteria to confer resistance to beta-lactam antibiotics. By inhibiting these enzymes, tazobactam protects piperacillin from degradation and extends its spectrum of activity to include many beta-lactamase-producing bacteria. Tapectam is indicated for the treatment of severe systemic and/or local bacterial infections, including nosocomial pneumonia, ventilator-associated pneumonia, complicated intra-abdominal infections, and skin and soft tissue infections in adults and pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tapectam.